4 research outputs found
ЭФФЕКТИВНОСТЬ ЗОЛЕДРОНОВОЙ КИСЛОТЫ В ПРОФИЛАКТИКЕ КОСТНЫХ МЕТАСТАЗОВ У ПАЦИЕНТОВ С МЕСТНО-РАСПРОСТРАНЕННЫМ РАКОМ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
The analysis of the performed study has established that zoledronic acid is an effective agent in multimodality therapy for locally advanced prostate cancer (PC) and allows long-term stabilization of bone tissue. In addition, there is evidence for the efficacy of zoledronic acid in preventing bone metastases (BM) and increasing the time to the first BM. The currently accumulated experience with zoledronic acid used in PC permits one to consider its use as standard concomitant therapy.На основании анализа проведенного исследования установлено, что золедроновая кислота является эффективным препаратом в комплексной терапии местно-распространенного рака предстательной железы (РПЖ) и позволяет стабилизировать в течение длительного времени состояние костной ткани. Кроме того, подтверждена эффективность золедроновой кислоты в профилактике костных метастазов (КМ), а также в увеличении времени до появления первого КМ. Накопленный к настоящему времени опыт использования золедроновой кислоты при РПЖ позволяет рассматривать ее назначение как стандартную сопроводительную терапию
EFFICACY OF ZOLEDRONIC ACID IN THE PREVENTION OF BONE METASTASES IN PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER
The analysis of the performed study has established that zoledronic acid is an effective agent in multimodality therapy for locally advanced prostate cancer (PC) and allows long-term stabilization of bone tissue. In addition, there is evidence for the efficacy of zoledronic acid in preventing bone metastases (BM) and increasing the time to the first BM. The currently accumulated experience with zoledronic acid used in PC permits one to consider its use as standard concomitant therapy
EFFICACY OF ZOLEDRONIC ACID IN THE PREVENTION OF BONE METASTASES IN PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER
<p>The analysis of the performed study has established that zoledronic acid is an effective agent in multimodality therapy for locally advanced prostate cancer (PC) and allows long-term stabilization of bone tissue. In addition, there is evidence for the efficacy of zoledronic acid in preventing bone metastases (BM) and increasing the time to the first BM. The currently accumulated experience with zoledronic acid used in PC permits one to consider its use as standard concomitant therapy.</p